Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Hannah Wuellner

Nurse Practitioner, Acute Care Saint Louis, MO Nurse Practitioner

NPI 1245977040 CMS profile 11368831

12700 Southfork Rd Ste 280, Saint Louis, MO 63128

Open in the dashboard

General payments

$1,131

48 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Hannah Wuellner of Saint Louis, MO is reported in the CMS Open Payments database as having received $1,131 across 48 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 76th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $388 17
2024 General $400 15
2023 General $303 14
2022 General $40 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hannah Wuellner
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Hannah Wuellner were reported at $388. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Hannah Wuellner Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $123 $38–$327 $132
2022 $40 $130 $44–$369 $149
2023 $303 $144 $49–$410 $160
2024 $400 $146 $48–$433 $164
2025 $388 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AstraZeneca Pharmaceuticals LP $271 15 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $203 7 payments
  3. Grifols USA, LLC $107 4 payments
  4. Actelion Pharmaceuticals US, Inc. $100 1 payment
  5. Insmed, Inc. $81 4 payments
  6. Regeneron Healthcare Solutions, Inc. $73 2 payments
  7. AbbVie, Inc. $45 2 payments
  8. Verona Pharma, Inc. $42 2 payments
  9. United Therapeutics Corporation $41 2 payments
  10. Baxter Healthcare $29 1 payment
  11. Other $138 8 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $1,131 48 payments
Products named General payments · program years 2022–2025
  1. Prolastin-C Liquid $107 4 payments
  2. OPSUMIT $100 1 payment
  3. UPTRAVI $100 1 payment
  4. BREZTRI $100 6 payments
  5. Arikayce $81 4 payments
  6. AIRSUPRA $77 4 payments
  7. OFEV Respiratory $60 2 payments
  8. OFEV Respiratory $59 2 payments
  9. TEZSPIRE $57 3 payments
  10. TEFLARO $45 2 payments
  11. Other $522 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

2,512

Median for Nurse Practitioner: 389

Drug cost

$837,643

Median for Nurse Practitioner: $21,885

Branded share of claims

56.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ofev Nintedanib Esylate Brand 22 $289,576
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 272 $201,146
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 109 $81,448
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 126 $62,949
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 49 $28,712
Eliquis Apixaban Brand 44 $23,148
Advair Hfa Fluticasone Propion/Salmeterol Brand 57 $21,991
Breo Ellipta Fluticasone/Vilanterol Brand 50 $20,133
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 75 $16,974
Symbicort Budesonide/Formoterol Fumarate Brand 42 $12,852

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$25,503

Medicare's payments for the services billed

Medicare patients

269

Average age 75

Services billed

344

161 women, 108 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 70%
Arthritis 58%
Ischemic heart disease 50%
Chronic kidney disease 42%
Heart failure 39%
Depression 38%
Diabetes 35%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OFEV
  • Boehringer Ingelheim Pharmaceuticals, Inc. $60
$60 22 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $58
$58 — —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $50
$50 — —
UPTRAVI
  • Actelion Pharmaceuticals US, Inc. $50
$50 — —
Prolastin-C Liquid
  • Grifols USA, LLC $47
$47 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

48 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record